Invent Medic Sweden (IMS) investor relations material

Executive summary

• Q3 revenue was SEK 1,420k vs SEK 1,818k YoY; pre-tax loss narrowed to SEK 782k from SEK 1,149k, extending the improvement trend.

• 9M revenue was SEK 5,405k vs SEK 5,648k; pre-tax loss narrowed to SEK 2,432k from SEK 4,088k.

• Cost restructuring and the 2026 capital raise strengthened the financial position; focus now shifts to commercial growth and market penetration.

Financial highlights

• Q3 gross profit was SEK 1,188k vs SEK 1,442k; total operating costs fell to SEK 2,140k from SEK 2,911k.

• 9M gross profit was SEK 4,360k vs SEK 4,423k; operating costs declined to SEK 7,674k from SEK 9,596k.

• Q3 net loss was SEK 782k vs SEK 1,149k; 9M net loss was SEK 2,432k vs SEK 4,088k.

• Q3 operating cash flow was negative SEK 861k vs negative SEK 1,654k; 9M operating cash flow was negative SEK 2,784k vs negative SEK 4,250k.

Outlook and guidance

• Priorities are accelerating sales, increasing market presence and developing commercial partnerships to pursue sustainable growth and eventual break-even.

• Sweden is the home-market platform; efforts target higher penetration through regional agreements, while international resources focus on markets with greatest potential.

• Near-term focus markets include the UK and Norway; longer-term plans include adding products and brands through development, partnerships and/or acquisitions.